Patient-reported ejaculatory function and satisfaction in men with lower urinary tract symptoms/benign prostatic hyperplasia

Min Chul Cho¹, Jung Kwon Kim², Sang Hoon Song³, Sung Yong Cho¹, Sang Wook Lee⁴, Soo Woong Kim³, Jae-Seung Paick²

This study aimed to investigate perceived ejaculatory function/satisfaction before treatment for lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and to identify associations between specific categories of ejaculatory dysfunctions (EjDs) and LUTS. A total of 1574 treatment-naïve men with LUTS/BPH were included in this study. All patients underwent routine evaluation for LUTS/BPH including the International Index of Erectile Function and a 5-item questionnaire developed to assess ejaculatory volume/force/pain/satisfaction/latency time. Patients who had sexual intercourse over the past 4 weeks were classified as sexually active group. A total of 783 patients were categorized as sexually active group. Decreased ejaculatory volume and force were reported by 53.4% and 55.7% of 783 sexually active men, respectively. There was a strong correlation between ejaculatory volume and force. Ejaculatory pain/discomfort, premature ejaculation (PE), and delayed ejaculation (DE) were reported in 41.0%, 16.3%, and 41.4% of the patients, respectively. Over 40.0% of men without decreased ejaculatory volume/force were satisfied with ejaculatory function, whereas approximately 6.0% of men with decreased volume/force were satisfied with ejaculatory function. About 30.0% of men with decreased volume/force had orgasmic dysfunction, while approximately 10.0% of men without decreased volume/force did. Decreased ejaculatory volume or force was associated with LUTS severity after adjusting for other influencing factors including testosterone level, erectile function, and prostate size on ultrasonography, but PE or DE or ejaculatory pain/discomfort was not. In conclusion, a considerable portion of men with LUTS/BPH appear to have a variety of EjDs. Ejaculatory volume/force and satisfaction/orgasm do not always appear to be concordant. Ejaculatory volume or force is independently associated with LUTS severity, whereas PE or DE or ejaculatory pain/discomfort is not.

Asian Journal of Andrology (2018) 20, 69–74; doi: 10.4103/aja.aja_11_17; published online: 2 May 2017

Keywords: dysfunction; ejaculation; lower urinary tract symptoms (LUTS); satisfaction

INTRODUCTION

Ejaculatory dysfunction (EjD) is one of the most common male sexual disorders. It can negatively affect quality of life (QoL) in many men.¹ EjD includes premature ejaculation (PE), delayed ejaculation (DE), anejaculation, retrograde ejaculation, and painful ejaculation.² Although erectile dysfunction (ED) and, more recently, PE have been extensively studied, there are limited data on DE, anejaculation, and decreased ejaculatory volume (DEV) or force (DEF). Furthermore, although some epidemiologic studies have reported an association between EjD and lower urinary tract symptoms (LUTS),⁴⁻⁷ there are limited data on the degree of satisfaction with ejaculatory ability or on the association between LUTS and specific categories of EjDs in men with LUTS.

A recent meta-analysis suggests that α-blockers and 5α-reductase inhibitors, which have been most commonly prescribed for medical treatment of LUTS/benign prostatic hyperplasia (BPH), are associated with 5.88- and 2.73-times higher risk of EjDs than placebo, respectively.¹⁰ A previous study reported that 70% of sexually active men would not agree to continue medical treatments for BPH if they had to experience adverse effects including EjD.¹¹ Loss of ejaculation is a common complication of BPH surgery.¹² Previous studies of men with LUTS/BPH reported that 47.0%–94.0% considered DEV or painful ejaculation as a problem.⁷,¹³ Thus, effectively counseling patients regarding their ejaculatory function before treatment for LUTS may help improve treatment satisfaction and yield better QoL. In addition, given the era where particular attention is paid to patients’ QoL and, thereby, effect of LUTS/BPH treatment on their ejaculatory function cannot be overlooked, the presence or absence of EjDs before treatment in men with LUTS/BPH may influence the selection of a therapeutic option.

The aim of this study was to investigate perceived ejaculatory function and satisfaction before the initiation of treatment in men with LUTS, and to identify significant associations between specific categories of EjDs and LUTS after adjusting for other confounding factors.
MATERIALS AND METHODS
Between April 2005 and May 2011, a total of 1574 men, who visited the department of urology in our hospital because of LUTS/BPH, were treatment naïve for LUTS, and did not fall under the following exclusion criteria, were included in this study. The exclusion criteria were previous diagnosis of urethral stricture, prostate or bladder cancer, neurogenic bladder disease, previous history of urological surgery, previous or current medication with α-blockers or 5α-reductase inhibitors or type-5 phosphodiesterase inhibitors or anti-cholinergic medications, and incomplete data. We retrospectively reviewed our prospectively collected database. This study was approved by our Institutional Review Board.

Evaluations for all patients included medical history, physical examination including digital rectal examination, urinalysis, serum creatinine, serum prostate-specific antigen (PSA), serum testosterone, transrectal ultrasonography (TRUS), the International Prostate Symptom Score (IPSS), the Overactive Bladder Symptom Score, and the International Index of Erectile Function (IIEF). Furthermore, patient-reported ejaculatory function and satisfaction were assessed by a 5-item questionnaire (EjQ) modified from the existing validated questionnaires about male sexual function (Brief Male Sexual Function Inventory, Ejaculation function domain of Male Sexual Health Questionnaire, and Premature Ejaculation Diagnostic Tool). The EjQ composed of five questions rated on a 6-point scale to assess ejaculation function and satisfaction concerning ejaculatory volume (EjQ1), ejaculatory force (EjQ2), pain/discomfort on ejaculation (EjQ3), degree of satisfaction with ejaculatory ability (EjQ4), and time from penile intromission to ejaculation (EjQ5) (Supplementary Information).

Patients who responded in the IIEF of a lack of sexual stimulation or intercourse over the past 4 weeks were classified as sexually inactive group. All the other responders were classified as sexually active group. LUTS severity was classified based on total IPSS as mild (score ≤7) and moderate to severe (score ≥8). According to the erectile function (EF) domain score of the IIEF, ED severity was classified into five categories as follows: no ED (score of 26–30), mild (score of 22–25), mild to moderate (score of 17–21), moderate (score of 11–16), and severe (score of 6–10). Patients with EjQ1 and EjQ2 score of 1 or 2 were considered as having DEV and DEF, respectively. Patients with EjQ3 score of 1–4 were considered as having pain/discomfort on ejaculation. Patients with EjQ5 score of 1 (short time) or 2 (very short time) and those with EjQ5 score of 4 (long time) or 5 (very long time) were considered as having PE and DE, respectively. Patients with EjQ4 score of 4 (moderately satisfied) or 5 (very satisfied) were considered as being satisfied with their ejaculation ability.

Statistical comparisons between groups were performed using χ² test or Fisher’s exact test for categorical variables. In terms of continuous variables, the independent t-test and Mann–Whitney U-test were used for normally distributed data and skewed data, respectively. Spearman’s correlation coefficient was calculated to estimate the association between each ejaculatory function. Multivariate logistic regression analyses were performed to examine the association between ejaculatory problems and LUTS severity with adjustment for confounding variables of age, body mass index, presence of comorbidities, serum PSA, testosterone level, total prostate volume on TRUS, IIEF-EF score, and sexual desire domain score of the IIEF. P < 0.05 was considered to indicate statistical significance and all tests were two sided. SPSS version 20.0 for Windows software (SPSS Inc., Chicago, IL, USA) was used for analyses.

RESULTS
Comparison in patient characteristics between sexually active and sexually inactive groups
A total of 783 patients (49.7%) had sexual intercourse over the 4 weeks prior to this study (sexually active group), whereas 791 patients (50.3%) had not (sexually inactive group). Table 1 summarizes the baseline characteristics of the two groups. Most of the patients in the sexually inactive group (93.8%) almost never/never felt sexual desire, according to their response to IIEF question 11. On the other hand, 71% of the patients in the sexually active group had considerable sexual desire (score ≥3). In the sexually active group, the percentages of men with severe, moderate, mild-to-moderate, and mild ED were 13.2%, 17.0%, 18.0%, and 16.7%, respectively. The remaining 275 men (35.1%) did not complain of ED according to the IIEF-EF score.

Ejaculatory function in sexually active men with LUTS/BPH
Figure 1 summarizes the patients’ responses to the EjQ questionnaire. In the sexually active group, 53.4% and 55.7% of the patients reported DEV and DEF, respectively. There was a strong correlation between DEV and DEF (Spearman’s correlation coefficient of 0.823; P < 0.001).

According to their responses to IIEF question 10, the percentage of men with orgasmic dysfunction (score of 1 or 2) was 21.6% in the overall sexually active group, 30.4% of men with DEV, and 30.2% of men with DEF. The percentage of men with orgasmic dysfunction in the subset of patients without DEV was 11.5%. The rate of orgasmic dysfunction in the subset of men without DEV was 10.6%.

In the sexually active group, pain/discomfort during ejaculation was reported by 41.0% of the patients. The ejaculatory latency time was reported to be very long in 5.8%, long in 10.5%, short in 26.6%, and very short in 14.8% of patients.
Table 1: Comparison of baseline characteristics between sexually active and inactive groups

|                          | Sexually active group (n=783) | Sexually inactive group (n=791) | Total (n=1574) |
|--------------------------|------------------------------|--------------------------------|----------------|
| Age (year)               | 64.01±8.87                   | 69.76±8.62                     | 66.90±9.20     |
| BMI (kg m⁻²)             | 24.34±3.08                   | 24.10±4.13                     | 24.22±3.65     |
| Waist circumference (cm) | 87.78±9.87                   | 88.30±9.42                     | 88.03±9.65     |
| Hypertension, n (%)      | 242 (30.9)                   | 296 (37.4)                     | 538 (34.2)     |
| Diabetes mellitus, n (%) | 82 (10.5)                    | 118 (14.9)                     | 200 (12.7)     |
| PSA (ng ml⁻¹)            | 2.33±2.76                    | 2.58±3.60                      | 2.45±3.22      |
| Testosterone (ng ml⁻¹)   | 4.08±1.55                    | 4.20±1.90                      | 4.14±1.73      |
| Total prostate volume (ml)| 42.03±18.83                  | 44.02±17.17                    | 43.03±18.03    |
| Transition zone volume (ml)| 19.56±6.57                  | 21.17±12.64                    | 20.37±14.72    |
| Maximum urine flow rate' (ml s⁻¹)| 13.93±10.27              | 12.29±9.70                     | 13.10±10.01    |
| Postvoid residual urine volume’ (ml)| 32.46±5.66             | 41.99±7.38                     | 37.30±6.79     |
| Bladder voiding efficiency’ (%) | 87.21±17.37              | 83.11±21.00                    | 85.13±19.40    |
| Daytime frequency on voiding diary | 7.76±2.87                | 7.69±2.71                      | 7.72±2.79      |
| Nocturnal frequency on voiding diary | 1.53±1.25                   | 1.85±1.38                     | 1.70±1.33      |
| Nocturnal polyuria index' | 0.35±0.13                    | 0.38±0.14                      | 0.36±0.13      |
| Subtotal voiding symptom score | 8.76±5.38              | 9.01±5.63                      | 8.89±5.51      |
| Subtotal storage symptom score' | 5.87±3.27               | 6.35±3.74                      | 6.12±3.52      |
| Total IPSS               | 14.64±7.72                   | 15.36±8.40                     | 15.00±8.08     |
| QoL index'               | 3.40±1.40                    | 3.54±1.41                      | 3.47±1.39      |
| Total OABSS’             | 4.69±3.45                    | 5.29±3.46                      | 5.01±3.46      |
| IIEF Q11 (How often have you felt sexual desire?)*, n (%) | 58 (7.4)                  | 742 (93.8)                     | 800 (50.8)     |
| Almost never/never       | 169 (21.6)                   | 28 (3.5)                       | 197 (12.5)     |
| A few times              | 221 (28.2)                   | 8 (1.0)                        | 229 (14.5)     |
| Sometimes                | 8 (1.0)                      | 1 (0.1)                        | 10 (0.6)       |
| Most times               | 95 (12.1)                    | 12 (1.5)                       | 107 (6.8)      |
| Almost always/always     | 240 (30.7)                   | 1 (0.1)                        | 241 (15.3)     |
| IIEF-EF domain score*    | 20.51±7.70                   | 1.39±1.71                      | 10.92±11.06    |
| IIEF-OF domain score*    | 7.39±2.80                    | 0.08±0.57                      | 3.71±4.17      |
| IIEF-SD domain score*    | 6.10±1.79                    | 2.21±0.95                      | 4.14±2.42      |
| IIEF-IS domain score*    | 7.93±2.96                    | 0.06±0.51                      | 3.98±4.47      |
| IIEF-OS domain score*    | 6.17±2.00                    | 2.15±0.89                      | 4.16±2.54      |
| Total IIEF score*        | 48.04±15.73                  | 5.85±3.53                      | 26.84±23.97    |

* P<0.05: comparison between the sexually active and sexually inactive groups. BMI: body mass index; PSA: prostate-specific antigen; IPSS: International Prostate Symptom Score; QoL: quality of life; OABSS: Overactive Bladder Symptom Score; IIEF: International Index of Erectile Function; EF: erectile function; OF: orgasmic function; SD: sexual desire; IS: intercourse satisfaction; OS: overall satisfaction

Perceived ejaculatory satisfaction in sexually active men with LUTS/BPH

In the sexually active group, 22.2% of the patients were satisfied with their ejaculatory function (Figure 1). According to their response to the EjQ4, only 6.0% of the 418 men with DEV and only 5.5% of the 436 men with DEF were satisfied with their ejaculatory function (Figure 2). On the other hand, 41.4% of the 360 men without DEV and 43.9% of the 342 men without DEF were satisfied with their ejaculatory ability.

Correlation between ejaculatory problems and LUTS severity in sexually active men with LUTS/BPH

On multivariate analysis, volume or force of ejaculation was associated with LUTS severity after adjustment for other variables (P = 0.007 and P = 0.017, respectively; Table 2). Patients with moderate-to-severe LUTS had 3.007-times or 2.803-times higher risk of DEV or DEF, respectively, than those with mild LUTS. However, the LUTS severity was not associated with PE or DE or pain/discomfort during ejaculation (Table 3 and 4). Lower IIEF-EF domain score and smaller prostate volume were associated with DE (P = 0.015 and P = 0.041, respectively; Table 3). Older age was associated with PE (P = 0.029) and younger age with pain/discomfort during ejaculation (P < 0.001; Table 3 and 4).

DISCUSSION

There have been limited data on patient-reported ejaculatory function and satisfaction in men with LUTS/BPH. This study extends the current state of knowledge regarding them. There were four main findings in our study. First, nearly half of the sexually active men with LUTS/BPH had DEV or DEF. There was a strong correlation between ejaculatory volume and force. Second, patient-reported pain/discomfort during ejaculation, PE, and DE were observed in 41.0%, 16.3%, and 41.4% of the sexually active men with LUTS/BPH, respectively. Third, although the degree of ejaculatory satisfaction or orgasm in men without DEV or DEF was higher than that in those with DEV or DEF, about half of the men without DEV or DEF as well as most of the patients with DEV or DEF were not satisfied with their ejaculatory ability. Furthermore, about 70% of men with DEV or DEF did not have orgasmic dysfunction. Fourth, the ejaculatory volume or force was associated with LUTS severity after adjustment for other influencing factors. However, the LUTS severity was not associated with PE or DE or pain/discomfort during ejaculation.

In our study, 53.4% of the sexually active men with LUTS/BPH had DEV. Previous studies similarly reported DEV in 47.0%–63.0% of men with LUTS/BPH. These findings carry significant implications in men with LUTS/BPH, because BPH surgeries and selective α-1A-adrenergic
Ejaculatory function in men with LUTS/BPH
MC Cho et al

Table 2: Odds ratios of potential risk factors for decreased volume or force of ejaculation, according to the logistic regression analysis

|                        | Decreased volume of ejaculation (EjQ1 score of 1 or 2) | Decreased force of ejaculation (EjQ2 score of 1 or 2) |
|------------------------|------------------------------------------------------|-----------------------------------------------------|
|                        | OR (95% CI)                                          | Adjusted OR (95% CI)                                 |
| Age                    |                                                      |                                                     |
| 1.025 (1.000–1.050)    | 1.099 (0.964–1.056)                                  |                                                     |
| BMI                    |                                                      |                                                     |
| 0.999 (0.926–1.078)    | 0.992 (0.870–1.211)                                  |                                                     |
| Diabetes mellitus      |                                                      |                                                     |
| Absence                | 1.000                                                |                                                     |
| Presence               | 0.637 (0.334–1.214)*                                 | 0.314 (0.115–0.856)*                                 |
| Hypertension           |                                                      |                                                     |
| Absence                | 1.000                                                |                                                     |
| Presence               | 1.169 (0.707–1.931)                                  | 2.033 (0.816–5.065)                                 |
| Serum PSA              | 1.021 (0.933–1.117)                                  | 1.086 (0.875–1.349)                                 |
| Serum testosterone     | 0.980 (0.796–1.207)                                  | 0.947 (0.745–1.204)                                 |
| Total prostate volume  | 1.000 (0.990–1.010)                                  | 0.997 (0.972–1.022)                                 |
| IIEF-EF score          | 0.906 (0.872–0.943)*                                 | 0.886 (0.813–0.965)*                                |
| IIEF-sexual desire score| 0.626 (0.534–0.734)*                                | 0.939 (0.694–1.271)                                 |
| LUTS severity          |                                                      |                                                     |
| Mild                   | 1.000                                                |                                                     |
| Moderate to severe     | 1.912 (1.143–3.200)*                                 | 3.007 (1.353–6.682)*                                |

aP<0.05. BMI: body mass index; PSA: prostate-specific antigen; IIEF: International Index of Erectile Function; EF: erectile function; LUTS: lower urinary tract symptoms; OR: odds ratio; CI: confidence interval; EjQ: ejaculation questionnaire

In our study, men with moderate-to-severe LUTS were 3 times more likely to have DEF than those with mild LUTS. Given that men with moderate-to-severe LUTS seek medical advice from clinicians more frequently than those with mild LUTS, the BPH treatments used to alleviate relatively severe symptoms may exact a toll of aggravated EjDs such as further decrease in an ejaculatory volume. In addition, an ejaculatory force might be affected by BPH treatments in the same manner as an ejaculatory volume. In our study, 55.7% of the sexually active men with LUTS/BPH had DEF. The percentage of patients with DEF was very similar with the prevalence of DEV; this correlation is further supported by our finding of the strong correlation between ejaculatory volume and force. In our study, 77.8% of the sexually active men with LUTS/BPH were not satisfied with their ejaculatory function. Furthermore, 58.6% of the 360 men without DEV and 56.1% of the 342 men without DEF were not satisfied with their ejaculatory function. Taken together, a considerable portion of sexually active men with LUTS/BPH appear to have ejaculatory problems including DEV or DEF and dissatisfaction with their ejaculatory ability before BPH treatment.

Our findings indicate that a considerable portion of clinicians might change their indifference in ejaculatory function of men with LUTS/BPH because they may be bothered by their ejaculatory function. In these patients, EjDs should not be overlooked, particularly in men with moderate-to-severe LUTS. Therefore, we think that evaluation of ejaculatory function and satisfaction before the initiation of treatment in men with LUTS/BPH may be a reasonable step. Furthermore, we recommend that, together with baseline ejaculatory function of patients, the impact of LUTS/BPH treatments on ejaculatory function or satisfaction should be explained to those with LUTS who are bothered enough to consider therapy because it may have an adverse impact on ejaculatory function or satisfaction to varying degrees.

Our study noted that 16.3% of the sexually active men with LUTS/BPH had PE, which was relatively lower compared to results (26.7%–29.1%) of a recent study involving a small cohort. However, the prior study was limited by the small sample size and the absence of assessment of sexual activity over the most recent period. Our study with a relatively larger cohort may provide more useful baseline data regarding PE in the sexually active men with LUTS/BPH. Meanwhile, our data showed that 41.4% of the sexually active men with LUTS/BPH had DE.

As expected, men without DEV or DEF had higher degree of ejaculatory satisfaction or orgasm compared to those with DEV or DEF. Interestingly, our study noted that 58.6% of men without DEV or 56.1% of those without DEF were not satisfied with their ejaculatory ability. In addition, 69.6% of men with DEV and 69.8% of men with DEF did not have orgasmic dysfunction. These findings indicate that ejaculatory volume/force and satisfaction about ejaculatory function or orgasm are not always concordant.

Most of the prior community-based studies have suggested that LUTS are strongly associated with DEV. In addition, previous studies have demonstrated that BPH treatments may have an adverse impact on EjDs including loss of ejaculation.10,12

Receptor blockers may aggravate EjD including loss of ejaculation.10,12 In our study, men with moderate-to-severe LUTS were 3 times more likely to have DEF than those with mild LUTS. Given that men with moderate-to-severe LUTS seek medical advice from clinicians more frequently than those with mild LUTS, the BPH treatments used to alleviate relatively severe symptoms may exact a toll of aggravated EjDs such as further decrease in an ejaculatory volume. In addition, an ejaculatory force might be affected by BPH treatments in the same manner as an ejaculatory volume. In our study, 55.7% of the sexually active men with LUTS/BPH had DEF. The percentage of patients with DEF was very similar with the prevalence of DEV; this correlation is further supported by our finding of the strong correlation between ejaculatory volume and force. In our study, 77.8% of the sexually active men with LUTS/BPH were not satisfied with their ejaculatory function. Furthermore, 58.6% of the 360 men without DEV and 56.1% of the 342 men without DEF were not satisfied with their ejaculatory function. Taken together, a considerable portion of sexually active men with LUTS/BPH appear to have ejaculatory problems including DEV or DEF and dissatisfaction with their ejaculatory ability before BPH treatment.

Our findings indicate that a considerable portion of clinicians might change their indifference in ejaculatory function of men with LUTS/BPH because they may be bothered by their ejaculatory function. In these patients, EjDs should not be overlooked, particularly in men with moderate-to-severe LUTS. Therefore, we think that evaluation of ejaculatory function and satisfaction before the initiation of treatment in men with LUTS/BPH may be a reasonable step. Furthermore, we recommend that, together with baseline ejaculatory function of patients, the impact of LUTS/BPH treatments on ejaculatory function or satisfaction should be explained to those with LUTS who are bothered enough to consider therapy because it may have an adverse impact on ejaculatory function or satisfaction to varying degrees.

Our study noted that 16.3% of the sexually active men with LUTS/BPH had PE, which was relatively lower compared to results (26.7%–29.1%) of a recent study involving a small cohort.14 However, the prior study was limited by the small sample size and the absence of assessment of sexual activity over the most recent period. Our study with a relatively larger cohort may provide more useful baseline data regarding PE in the sexually active men with LUTS/BPH. Meanwhile, our data showed that 41.4% of the sexually active men with LUTS/BPH had DE.

As expected, men without DEV or DEF had higher degree of ejaculatory satisfaction or orgasm compared to those with DEV or DEF. Interestingly, our study noted that 58.6% of men without DEV or 56.1% of those without DEF were not satisfied with their ejaculatory ability. In addition, 69.6% of men with DEV and 69.8% of men with DEF did not have orgasmic dysfunction. These findings indicate that ejaculatory volume/force and satisfaction about ejaculatory function or orgasm are not always concordant.

Most of the prior community-based studies have suggested that LUTS are strongly associated with DEV. In addition, previous
Table 3: Odds ratios of potential risk factors for premature or delayed ejaculation, according to the logistic regression analysis

|                             | Premature ejaculation (EjQ5 score of 1 or 2) | Delayed ejaculation (EjQ5 score of 4 or 5) |
|-----------------------------|---------------------------------------------|--------------------------------------------|
|                             | OR (95% CI)                                 | Adjusted OR (95% CI)                       | OR (95% CI)                        | Adjusted OR (95% CI) |
| Age                         | 1.002 (0.985–1.018)                         | 0.942 (0.911–0.976)                       | 1.036 (1.012–1.061)               | 0.991 (0.964–1.019)  |
| BMI                         | 0.964 (0.915–1.015)                         | 1.022 (0.953–1.096)                       | 1.021 (0.959–1.088)               | 0.940 (0.869–1.016)  |
| Diabetes mellitus           |                                             |                                            | 0.837 (0.609–1.151)               | 1.026 (0.868–1.213)  |
| Absence                     | 1.000                                       | 1.000                                      | 1.000                             | 1.000                   |
| Presence                    | 0.750 (0.462–1.215)                         | 1.256 (0.520–3.037)                       | 1.221 (0.679–2.196)               | 0.616 (0.290–1.310)  |
| Hypertension                |                                             |                                            | 1.000                             | 1.000                   |
| Absence                     | 1.000                                       | 1.000                                      | 1.000                             | 1.000                   |
| Presence                    | 0.837 (0.609–1.151)                         | 1.291 (0.703–2.369)                       | 1.694 (1.135–2.526)               | 0.919 (0.563–1.498)  |
| Serum PSA                   | 0.956 (0.900–1.015)                         | 1.017 (0.916–1.129)                       | 1.083 (1.015–1.155)               | 0.954 (0.841–1.082)  |
| Serum testosterone          | 0.975 (0.860–1.105)                         | 1.027 (0.845–1.249)                       | 1.035 (0.879–1.219)               | 0.975 (0.840–1.133)  |
| Total prostate volume       | 0.991 (0.984–0.999)                         | 1.011 (0.994–1.028)                       | 1.013 (1.006–1.021)               | 0.987 (0.975–0.999)  |
| IIEF-IEF score              | 0.936 (0.917–0.955)                         | 1.045 (0.988–1.106)                       | 1.008 (0.982–1.035)               | 0.942 (0.904–0.982)  |
| IIEF-sexual desire score    | 0.793 (0.728–0.865)                         | 0.950 (0.756–1.194)                       | 1.006 (0.902–1.123)               | 0.926 (0.783–1.096)  |
| LUTS severity               |                                             |                                            | 1.000                             | 1.000                   |
| Mild                        | 1.000                                       | 1.000                                      | 1.000                             | 1.000                   |
| Moderate to severe          | 0.971 (0.670–1.407)                         | 1.197 (0.559–2.563)                       | 0.936 (0.573–1.529)               | 0.887 (0.510–1.544)  |

Table 4: Odds ratios of potential risk factors for pain or discomfort on ejaculation, according to the logistic regression analysis

|                           | Pain or discomfort on ejaculation (EjQ3 score of 1 or 2 or 3 or 4) | Delayed ejaculation (EjQ5 score of 4 or 5) |
|---------------------------|--------------------------------------------------------------------|--------------------------------------------|
|                           | OR (95% CI)                                                       | Adjusted OR (95% CI)                       | OR (95% CI)                        | Adjusted OR (95% CI) |
| Age                       | 0.959 (0.943–0.975)                                               | 0.938 (0.911–0.966)                       | 1.036 (1.012–1.061)               | 0.991 (0.964–1.019)  |
| BMI                       | 0.999 (0.950–1.051)                                               | 1.022 (0.953–1.096)                       | 1.021 (0.959–1.088)               | 0.940 (0.869–1.016)  |
| Diabetes mellitus         |                                                                   |                                            | 0.837 (0.609–1.151)               | 1.026 (0.868–1.213)  |
| Absence                   | 1.000                                                             | 1.000                                      | 1.000                             | 1.000                   |
| Presence                  | 0.974 (0.605–1.566)                                               | 1.908 (0.947–3.843)                       | 1.000                             | 1.000                   |
| Hypertension              |                                                                   |                                            | 1.000                             | 1.000                   |
| Absence                   | 1.000                                                             | 1.000                                      | 1.000                             | 1.000                   |
| Presence                  | 0.875 (0.634–1.208)                                               | 0.895 (0.549–1.458)                       | 1.000                             | 1.000                   |
| Serum PSA                 | 0.999 (0.948–1.052)                                               | 0.979 (0.879–1.091)                       | 1.000                             | 1.000                   |
| Serum testosterone        | 1.009 (0.890–1.144)                                               | 1.024 (0.883–1.189)                       | 1.000                             | 1.000                   |
| Total prostate volume     | 1.000 (0.994–1.006)                                               | 1.004 (0.989–1.019)                       | 1.000                             | 1.000                   |
| IIEF-IEF score            | 0.971 (0.953–0.990)                                               | 0.978 (0.938–1.019)                       | 1.000                             | 1.000                   |
| IIEF-sexual desire score  | 0.958 (0.884–1.039)                                               | 1.026 (0.868–1.213)                       | 1.000                             | 1.000                   |
| LUTS severity             |                                                                   |                                            | 1.000                             | 1.000                   |
| Mild                      | 1.000                                                             | 1.000                                      | 1.000                             | 1.000                   |
| Moderate to severe        | 1.184 (0.813–1.724)                                               | 0.887 (0.509–1.546)                       | 1.000                             | 1.000                   |

A considerable portion of men visiting urologic clinic for LUTS/BPH appear to have a variety of EjDs. Thus, evaluation of various ejaculatory functions including ejaculatory volume, force, discomfort/pain, and satisfaction deserves consideration before the initiation of BPH treatment. This seems reasonable, given that the EjDs may be newly developed or further aggravated by the treatment. Furthermore, although it seems to be apparent that DEV or DEF significantly correlates with decreased ejaculatory satisfaction or orgasm, an

CONCLUSION

Despite these limitations, the present study may provide meaningful data. There remains a significant association between a reduced volume or force and LUTS severity in men with LUTS/BPH even after adjusting for confounding variables including testosterone level, erectile function, and prostate. The finding of no association between LUTS severity and PE or DE or pain/discomfort during ejaculation after adjusting for the confounders might also be meaningful.

MC Cho et al
ejaculatory volume/force and ejaculatory satisfaction/orgasm do not always appear to be concordant. Therefore, evaluation tools including ejaculatory satisfaction can be appropriate for assessing the ejaculatory function. Our study indicates that an ejaculation volume or force is independently associated with LUTS severity even after adjusting for confounding variables including erectile function, testosterone level, and prostate size, whereas PE or DE or pain/discomfort during ejaculation does not. Further studies are necessary to validate our findings.

**AUTHOR CONTRIBUTIONS**
MCC carried out substantial contributions to conception/design, data acquisition, data analysis, interpretation, drafting the manuscript, and statistical analysis. JKK, SHS, and SYC carried out substantial contributions to conception/design and data interpretation. SWL and SWK carried out data interpretation, critical revision of the manuscript for scientific and factual content, and helped to draft the manuscript. JSP carried out substantial contributions to conception/design, data analysis, interpretation, drafting the manuscript, supervision, and approved the final manuscript. All authors read and approved the final manuscript.

**COMPETING INTERESTS**
All authors declare no competing interests.

**ACKNOWLEDGMENTS**
This research was supported by the Materials and Components Technology Development Program of MOTIE/KEIT, Republic of Korea (10067258, 14140044, 14017515). This research was supported by the Materials and Components Technology Development Program of MOTIE/KEIT, Republic of Korea (10067258, 14140044, 14017515). This research was supported by the Materials and Components Technology Development Program of MOTIE/KEIT, Republic of Korea (10067258, 14140044, 14017515). This research was supported by the Materials and Components Technology Development Program of MOTIE/KEIT, Republic of Korea (10067258, 14140044, 14017515).

Supplementary information is linked to the online version of the paper on the Asian Journal of Andrology website.

**REFERENCES**
1. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, et al. Disorders of orgasm and ejaculation in men. J Sex Med 2010; 7: 1668–86.
2. McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med 2016; 13: 135–43.
3. Rosen R, Altewein J, Boyle P, Kirby RS, Lukacs B, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–49.
4. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436–42.
5. Chung WS, Nehra A, Jacobson DJ, Roberts RO, Rhodes T, et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc 2004; 79: 745–9.
6. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 2005; 96: 1339–54.
7. Frankel SJ, Donovan JL, Peters TI, Abrams P, Dabhiowala NF, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
8. Vallancien G, Emberton M, Harving N, van Mooreselaar RJ, Atf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–61.
9. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, et al. The impact of lower urinary tract symptoms on male sexual health. EpilUTS. BJU Int 2009; 103: 33–41.
10. Gacci M, Ficarra V, Sebastianielli A, Corona G, Serni S, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 2014; 11: 1554–66.
11. Fourcade RO, Theret N, Taieb C. Sexual function and opinion of patients treated for the first time for LUTS/BPH. Eur Urol Suppl 2008; 7: 169.
12. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–96.
13. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH, et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346–51.
14. Silangcruz JM, Chua ME, Morales ML Jr. Prevalence and factor association of premature ejaculation among adult Asian males with lower urinary tract symptoms. Prostate Int 2015; 3: 65–9.
15. Hartung R, Emberton M, Van Mooreselaar RJ, Harving N, Matzkin H, et al. Sexual dysfunction in 3,230 men with LUTS suggestive of BPH in Europe, Russia, Middle-East, Latin America and Asia. Eur Urol Suppl 2003; 2: 27.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©The Author(s)(2017)